Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart
Portfolio Pulse from
Abbott has announced the successful completion of the world's first in-human leadless left bundle branch area pacing procedures using its investigational AVEIR™ Conduction System Pacing leadless pacemaker system. The device has received FDA Breakthrough Device Designation, expediting its review.
December 17, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott's AVEIR™ CSP leadless pacemaker system has achieved a significant milestone with the first successful in-human procedures. The device's FDA Breakthrough Device Designation could expedite its market entry, potentially boosting Abbott's market position in cardiac care.
The successful completion of the first in-human procedures using Abbott's AVEIR™ CSP system and its FDA Breakthrough Device Designation are significant achievements. These developments could lead to expedited market entry and strengthen Abbott's position in the cardiac care market, likely having a positive short-term impact on its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100